Cardiovascular and cerebrovascular safety of ranibizumab 0.5 mg in diabetic macular edema

被引：0
|
作者：
Zarbin, Marco A. [1 ]
Ziemssen, Focke [2 ]
Margaron, Philippe [3 ]
Snow, Howard [3 ]
Dunger-Baldauf, Cornelia [3 ]
Hashmonay, Ron [3 ]
Bailey, Clare [4 ]
机构：
[1] Rutgers New Jersey Med Sch, Inst Ophthalmol & Visual Sci, Newark, NJ USA
[2] Univ Tubingen, Ctr Ophthalmol, Tubingen, Germany
[3] Novartis Pharma AG, Basel, Switzerland
[4] Bristol Eye Hosp, Clin Res Unit, Bristol BS1 2LX, Avon, England
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2015年 / 56卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
1410
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study)
    D S Dhoot
    D J Pieramici
    M Nasir
    A A Castellarin
    S Couvillion
    R F See
    N Steinle
    M Bennett
    M Rabena
    R L Avery
    [J]. Eye, 2015, 29 : 534 - 541
  • [2] Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study)
    Dhoot, D. S.
    Pieramici, D. J.
    Nasir, M.
    Castellarin, A. A.
    Couvillion, S.
    See, R. F.
    Steinle, N.
    Bennett, M.
    Rabena, M.
    Avery, R. L.
    [J]. EYE, 2015, 29 (04) : 534 - 541
  • [3] Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes
    Staurenghi, Giovanni
    Lai, Timothy Y. Y.
    Mitchell, Paul
    Wolf, Sebastian
    Wenzel, Andreas
    Li, Jun
    Bhaumik, Amitabha
    Hykin, Philip G.
    [J]. OPHTHALMOLOGY, 2018, 125 (06) : 850 - 862
  • [4] Two-Year Safety and Efficacy of Ranibizumab 0.5 mg in Diabetic Macular Edema Interim Analysis of the RESTORE Extension Study
    Lang, Gabriele E.
    Berta, Andras
    Eldem, Bora M.
    Simader, Christian
    Sharp, Dianne
    Holz, Frank G.
    Sutter, Florian
    Gerstner, Ortrud
    Mitchell, Paul
    [J]. OPHTHALMOLOGY, 2013, 120 (10) : 2004 - 2012
  • [5] Ranibizumab in diabetic macular edema
    Krispel, Claudia
    Rodrigues, Murilo
    Xin, Xiaoban
    Sodhi, Akrit
    [J]. WORLD JOURNAL OF DIABETES, 2013, 4 (06) : 310 - 318
  • [6] Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab
    Pieramici, Dante
    Nasir, Ma'an
    Castellarin, Alessandro
    See, Robert
    Couvillion, Steve
    Bennett, Michael
    Rabena, Melvin
    Giust, Jack
    Wan, Lisha
    Avery, Robert
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [7] Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study)
    Massin, Pascale
    Bandello, Francesco
    Garweg, Justus G.
    Hansen, Lutz L.
    Harding, Simon P.
    Larsen, Michael
    Mitchell, Paul
    Sharp, Dianne
    Wolf-Schnurrbusch, U. E. K.
    Gekkieva, Margarita
    Weichselberger, Andreas
    Wolf, Sebastian
    [J]. DIABETES CARE, 2010, 33 (11) : 2399 - 2405
  • [8] Pooled safety analysis in patients with visual impairment due to diabetic macular edema treated with 0.5 mg ranibizumab in RESOLVE and RESTORE trials
    Bandello, F.
    Lang, G. E.
    Schlingemann, R. O.
    Leclair, D.
    Weichselberger, A.
    [J]. DIABETOLOGIA, 2011, 54 : S454 - S454
  • [9] Cardiovascular and cerebrovascular safety of ranibizumab (RBZ) in diabetic macular edema (DME): A comprehensive patient-level meta-analysis at month 12
    Snow, Howard
    Singh, Natasha
    Parikh, Soumil
    Francom, Steven
    Dunger-Baldauf, Cornelia
    Haskova, Zdenka
    Margaron, Philippe
    Adamis, Anthony P.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [10] Benefit of continuing ranibizumab 0.5 mg treatment in diabetic macular edema patients with delayed initial visual response
    Bottoni, Ferdinando
    Dunger-Baldauf, Cornelia
    Margaron, Philippe
    Staurenghi, Giovanni
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
12345